Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

STI571

Known as: STI 571, STI-571 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Progression of pulmonary hypertension is associated with increased proliferation and migration of pulmonary vascular smooth… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Imatinib mesylate (STI571), a potent tyrosine kinase inhibitor, is successfully used in the treatment of chronic myelogenous… Expand
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
In clinical trials, the tyrosine kinase inhibitor STI571 has proven highly effective in reducing leukemic cell burden in chronic… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine… Expand
  • figure 1
  • table 4
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
STI571 (formerly known as CGP 57148B) is a protein-tyrosine kinase inhibitor that is currently in clinical trials for the… Expand
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2000
Highly Cited
2000
The 2-phenylaminopyrimidine derivative STI571 has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
2000
Highly Cited
2000
The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML). A small-molecule… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Targeting the tyrosine kinase activity of Bcr-Abl with STI571 is an attractive therapeutic strategy in chronic myelogenous… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?